Recent progress of nanomedicine in managing dry eye disease

Advances in Ophthalmology Practice and Research, Journal Year: 2024, Volume and Issue: 4(1), P. 23 - 31

Published: Jan. 29, 2024

Dry eye disease (DED) is a commonly reported ocular complaint that has garnered significant attention in recent research. The global occurrence of DED ranges from 5 % to 50 %, impacting substantial proportion individuals worldwide with increasing frequency. Although topical administration remains the mainstream drug delivery method for diseases, it suffers drawbacks such as low bioavailability, rapid metabolism, and frequent requirements. Fortunately, advancements nanomedicine offer effective solutions address aforementioned issues provide assistance treatment DED. considered multifactorial surface tear film, which integrity film function structure plays crucial role maintaining homeostasis surface. conventional involves utilization artificial products, cyclosporin, corticosteroids, mucin secretagogues, nonsteroidal anti-inflammatory drugs. Furthermore, presently field study, numerous clinical trials underway various nanotherapeutics including nanoemulsions, nanosuspensions, liposomes, micelles. Notably, some these innovative nanoformulations have already received FDA approval novel remedies DED, advancement poised enhanced prospects solve shortcomings existing treatments partially. This article provides an overview latest treatment, while expected witness remarkable breakthrough shortly development nanomedicine, bringing promising patients suffering conditions.

Language: Английский

---

Nanoceria-Mediated Cyclosporin A Delivery for Dry Eye Disease Management through Modulating Immune–Epithelial Crosstalk

ACS Nano, Journal Year: 2024, Volume and Issue: 18(17), P. 11084 - 11102

Published: April 18, 2024

Dry eye disease (DED) affects a substantial worldwide population with increasing frequency. Current single-targeting DED management is severely hindered by the existence of an oxidative stress–inflammation vicious cycle and complicated intercellular crosstalk within ocular microenvironment. Here, nanozyme-based drop, namely nanoceria loading cyclosporin A (Cs@P/CeO2), developed, which possesses long-term antioxidative anti-inflammatory capacities due to its regenerative activity sustained release (CsA). In vitro studies showed that dual-functional Cs@P/CeO2 not only inhibits cellular reactive oxygen species production, sequentially maintaining mitochondrial integrity, but also downregulates inflammatory processes repolarizes macrophages. Moreover, using flow cytometric single-cell sequencing data, in vivo therapeutic effect was systemically demonstrated, rebalances immune–epithelial communication corneal microenvironment less macrophage polarization, restrained stress, enhanced epithelium regeneration. Collectively, our data proved may provide insights into management.

Language: Английский

---

<p>A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments</p>

Clinical ophthalmology, Journal Year: 2020, Volume and Issue: Volume 14, P. 4187 - 4200

Published: Dec. 1, 2020

Abstract: Dry eye disease (DED) is a multifactorial of the ocular surface and tear film that has gained awareness as public health problem. Characteristics DED include instability, hyperosmolarity, inflammation, which can occur independently or may be sequela numerous diseases, surgery contact lens wear. Much been learned about impact to help affected individuals who report symptoms poor vision, pain, tearing. Recently, new research highlights importance role inflammation damage in DED—leading vicious cycle well loss homeostasis. immunopathophysiology characterized by four stages: initiation, amplification, recruitment, re-initiation. Cyclosporine proven valuable ophthalmic therapeutic for through its immunomodulatory actions regulation adaptive immune response. mechanism action described published literature myriad benefits all stages lend broad-based function particularly suitable addressing DED. Furthermore, cyclosporine unique goblet cell density improvement capabilities anti-apoptotic properties. Topical formulations are centered around highly lipophilic nature molecule. The aqueous solubility traditionally presented technical challenges drug delivery surface. Newer such cationic emulsions nanomicellar solutions address formulation, tissue concentration, challenges. Keywords: dry disease, A, emulsion, OTX-101, keratoconjunctivitis sicca

Language: Английский

---

Congenital aniridia beyond black eyes: From phenotype and novel genetic mechanisms to innovative therapeutic approaches

Progress in Retinal and Eye Research, Journal Year: 2022, Volume and Issue: 95, P. 101133 - 101133

Published: Oct. 22, 2022

Congenital PAX6-aniridia, initially characterized by the absence of iris, has progressively been shown to be associated with other developmental ocular abnormalities and systemic features making congenital aniridia a complex syndromic disorder rather than simple isolated disease iris. Moreover, foveal hypoplasia is now recognized as more frequent feature complete iris major visual prognosis determinant, reversing classical clinical picture this disease. Conversely, malformation also various anterior segment dysgenesis disorders caused PAX6-related genes, adding level genetic complexity for accurate molecular diagnosis aniridia. Therefore, recognition differential revealed much challenging thought, still remains under-investigated. Here, we update specific aniridia, emphasis on their genotype correlations, well provide new knowledge regarding PAX6 gene its mutational spectrum, highlight beneficial utility clinically implementing targeted Next-Generation Sequencing combined Whole-Genome increase diagnostic yield We present mechanisms underlying aniridia-like phenotypes. Finally, discuss appropriate medical surgical management aniridic eyes, innovative therapeutic options. Altogether, these clinical-genetic approaches will help accelerate time diagnosis, better determination management, confirm eligibility future trials or genetic-specific therapies.

Language: Английский

---

Advances in development of exosomes for ophthalmic therapeutics

Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 199, P. 114899 - 114899

Published: May 24, 2023

Language: Английский

---

Mucoadhesive liposomal delivery system synergizing anti-inflammation and anti-oxidation for enhanced treatment against dry eye disease

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 368, P. 318 - 328

Published: March 4, 2024

Language: Английский

---

Recent Developments About the Pathogenesis of Dry Eye Disease: Based on Immune Inflammatory Mechanisms

Frontiers in Pharmacology, Journal Year: 2021, Volume and Issue: 12

Published: Aug. 5, 2021

Dry eye disease is a common and frequently occurring ophthalmology with complex diverse causes, its incidence on the upward trend. The pathogenesis of DED still completely clear. However, immune response based inflammation has been recognized as core basis this disease. In review, we will systematically review previous research treatment in inflammation, analyze latest views hotspots, provide reference for prevention DED.

Language: Английский

---

Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(6), P. 1746 - 1746

Published: June 15, 2023

Chronic ocular diseases can seriously impact the eyes and could potentially result in blindness or serious vision loss. According to most recent data from WHO, there are more than 2 billion visually impaired people world. Therefore, it is pivotal develop sophisticated, long-acting drug delivery systems/devices treat chronic eye conditions. This review covers several nanocarriers that control disorders non-invasively. However, of developed still preclinical clinical stages. Long-acting systems, such as inserts implants, constitute majority clinically used methods for treatment due their steady state release, persistent therapeutic activity, ability bypass barriers. implants considered invasive technologies, especially those nonbiodegradable. Furthermore, vitro characterization approaches, although useful, limited mimicking truly representing vivo environment. focuses on systems (LADDS), particularly implantable (IDDS), formulation, characterization, application diseases.

Language: Английский

---

Aqueous-deficient dry eye disease: Preferred practice pattern guidelines on clinical approach, diagnosis, and management

Indian Journal of Ophthalmology, Journal Year: 2023, Volume and Issue: 71(4), P. 1332 - 1347

Published: April 1, 2023

Dry eye disease (DED) is a broad term that includes diverse group of clinical disorders. Aqueous-deficient dry (ADDE), subtype DED, characterized by decreased tear production the lacrimal gland. It can be seen in up to one-third individuals with DED and comorbid systemic autoimmune process or occur secondary an environmental insult. Since ADDE source long-term suffering severe visual impairment, early identification adequate treatment are imperative. Multiple etiologies underlie ADDE, it critical identify underlying cause not only improve ocular health but also overall quality life well-being affected individuals. This review discusses various highlights pathophysiology-based approach for evaluating contributors, outlines diagnostic tests, reviews options. We present current standards discuss ongoing research this field. Through review, we propose algorithm would useful ophthalmologist diagnosing managing ADDE.

Language: Английский

---

Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain

BMC Ophthalmology, Journal Year: 2024, Volume and Issue: 24(1)

Published: Jan. 22, 2024

Abstract Background The management of post-refractive surgery dry eye disease (DED) can be challenging in clinical practice, and patients usually show an incomplete response to traditional artificial tears, especially when it is complicated with ocular pain. Therefore, we aim investigate the efficacy combined topical 0.05% cyclosporine A 0.1% sodium hyaluronate treatment DED pain unresponsive tears. Methods We enrolled 30 who were Topical used for 3 months. They evaluated at baseline 1 months symptoms objective parameters, including Numerical Rating Scale (NRS), Neuropathic Pain Symptom Inventory modified Eye (NPSI-Eye), tear break-up time (TBUT), Schirmer I test (SIt), corneal fluorescein staining (CFS), sensitivity, nerve morphology. In addition, levels inflammatory cytokines neuropeptides measured using Luminex assay. Results After treatment, showed a statistically significant improvement surface index (OSDI), TBUT, SIt, CFS, sensitivity (all P < 0.01) linear mixed models. As NRS NPSI-Eye scores significantly reduced (both 0.05) positively correlated OSDI CFS scores. Additionally, IL-1β, IL-6, TNF-α improved better than pre-treatment ( = 0.01, 0.03, 0.02, respectively). Conclusion pain, film stability, discomfort, effectively controlling inflammation. Trial registration Registration number: NCT06043908.

Language: Английский

---